At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Pentoxifylline +1 moredrug
Likely dose
Pentoxifylline 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study
In Brief
A Phase 2 clinical trial evaluating Pentoxifylline and Vitamin E for Fibrosis. Completed, enrolled 54 participants across 1 site.
Detailed Summary
This study seeks to determine if a combination of Trental and Vitamin E prevents the development of radiation fibrosis in women treated with radiation for the definitive management of their breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2003
First PostedDec 2007
Primary CompletionMay 2010
Study CompletionJun 2012
TodayJul 2026
First PostedDec 31, 2007
Enrollment StartFeb 1, 2003
Primary CompletionMay 1, 2010
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 18.5 years ago
Interventions
Pentoxifyllinedrug
Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
Vitamin Edrug
Vitamin E (Over-the-counter) 400 I.U. once daily